Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
- 21 September 2006
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 46 (10), 1770-1777
- https://doi.org/10.1111/j.1537-2995.2006.00976.x
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus (SARS‐CoV) has been detected in the blood of infected individuals, which may have the potential to contaminate donated blood and plasma‐derived products in the event of a future outbreak. Effective methods for inactivating the SARS‐CoV in protein solutions are described in this report.This publication has 30 references indexed in Scilit:
- Design of a UV-C irradiation process for the inactivation of viruses in protein solutionsBiologicals, 2005
- Pathogen inactivation technology: cleansing the blood supplyJournal of Internal Medicine, 2005
- Detection of Severe Acute Respiratory Syndrome Coronavirus RNA in Plasma during the Course of InfectionJournal of Clinical Microbiology, 2005
- Heat sensitivity of a SARS‐associated coronavirus introduced into plasma productsVox Sanguinis, 2004
- Stability and inactivation of SARS coronavirusMedical Microbiology and Immunology, 2004
- Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin: Parametric and validation studiesBiologicals, 2003
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003
- Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells. Possible role of Dewar photoproducts in solar mutagenesisOnline Journal of Public Health Informatics, 2000
- Inactivation of Lipid-Enveloped Viruses in Proteins by CaprylateVox Sanguinis, 1991
- Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccineJournal of Medical Virology, 1987